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Fertility preservationSexual dysfunction is a common consequence of cancer treatment, affecting at least half of
men and women treated for pelvic malignancies and over a quarter of people with other
types of cancer. Problems are usually linked to damage to nerves, blood vessels, and hor-
mones that underlie normal sexual function. Sexual dysfunction also may be associated
with depression, anxiety, relationship conflict, and loss of self-esteem. Innovations in can-
cer treatment such as robotic surgery or more targeted radiation therapy have not had the
anticipated result of reducing sexual dysfunction. Some new and effective cancer treat-
ments, including aromatase inhibitors for breast cancer or chemoradiation for anal cancer
also have very severe sexual morbidity. Cancer-related infertility is an issue for younger
patients, who comprise a much smaller percentage of total cancer survivors. However,
the long-term emotional impact of being unable to have a child after cancer can be extre-
mely distressing. Advances in knowledge about how cancer treatments may damage fertil-
ity, as well as newer techniques to preserve fertility, offer hope to patients who have not
completed their childbearing at cancer diagnosis. Unfortunately, surveys in industrialised
nations confirm that many cancer patients are still not informed about potential changes
to their sexual function or fertility, and all modalities of fertility preservation remain
underutilised. After cancer treatment, many patients continue to have unmet needs for
information about restoring sexual function or becoming a parent. Although more research
is needed on optimal clinical practice, current studies suggest a multidisciplinary
approach, including both medical and psychosocial treatment options.
 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).
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Reproductive problems are among the most common and
distressing consequences of cancer treatment. Infertility
caused by cancer treatment only affects a minority of cancer
patients, since most are beyond the age of wanting to have a
child. Sexual dysfunction is a more universal threat. For most
men and women, reproductive problems persist long after
cancer treatment. We summarise the mechanisms of damage
to reproductive health from cancer treatment and suggest
ways to provide information and effective medical and psy-
chosocial interventions to cancer patients and survivors. We
also summarise recommendations for research and practice
from the authors, who comprised a panel of experts at the
first European Organisation for Research and Treatment of
Cancer (EORTC) Survivorship Summit.2. The prevalence of sexual dysfunction
related to cancer
Close to two-thirds of cancer survivors in the United States
were treated for pelvic or breast tumors [1], with at least a
50% prevalence of long-term, severe sexual dysfunction [2].
The situation is likely to be similar across Europe, given
comparable prevalence and types of cancer [3]. Most sexual
problems are not caused by the cancer itself, but by toxicities
of cancer treatment [2]. Although sexual problems are more
distressing for those under age 65 [4–6], and among patients
who are sexually active at cancer diagnosis [7–10], sexuality
remains important even for many geriatric cancer survivors
[11,12]. Damage during cancer treatment to pelvic nerves,
blood vessels, and organ structures leads to the highest rates
of sexual dysfunction [10,11,13–20], but problems are com-
mon even after lung cancer [8,21], haematologic malignancies
[22], or head and neck tumors [23]. Rates of sexual problems
are close to 33% in survivors of childhood cancer, with women
twice as likely as men to report dysfunction [24,25]. People
treated for central nervous system tumors in childhood or
adolescence may be limited in their adult relationships by
learning disabilities and continued dependence on their fam-
ilies of origin [24]. In both men and women, other side effects
of cancer treatment can lead to discontinuation of sexual
activity, particularly persistent fatigue [26], nausea, or urinary
and bowel incontinence [27–29].
2.1. Sexual problems in men
In men, the most common sexual problems are loss of desire
for sex and erectile dysfunction (ED) [2]. Less common, but
certainly distressing, are changes in the quality of orgasm,
difficulties reaching orgasm, and pain with erection or
orgasm [29,30]. Despite innovations such as laparoscopic
robotic radical prostatectomy, few men recover normal erec-
tions after pelvic cancer surgery. Even among men who had
excellent erections at baseline and are under age 65, fewer
than 25% retain or recover their former erection quality
[31–33]. Similarly, techniques to limit damage from radiation
therapy have been disappointing, with little evidence of supe-
rior erectile function after intensity-modulated radiationtherapy or proton therapy compared to computer guided
external beam protocols [34–39], and disappointing long-term
results after brachytherapy [20,34,39]. It is clear that a history
of prostate cancer is a major predictor of sexual dysfunction,
even for men on active surveillance. In the Scandinavian
Prostate Cancer Group Study, at 12-year follow-up, 84% of
men reported erectile dysfunction after radical prostatecto-
my, as did 80% on active surveillance, compared to only 43%
of matched control men who had not had prostate cancer
[40]. In the United States, the 10-year follow-up for the Pros-
tate, Lung, Colorectal, and Ovarian Cancer Screening Trial,
revealed that over 95% of men in each prostate cancer treat-
ment group had erection problems, again significantly worse
than rates in controls [41]. Another prospective cohort study
recently reported that by 15-yr follow-up, 87% of men with
localised disease have erectile dysfunction [20].
Men who have surgery for bladder [42] or rectal cancer
[14,43], or chemoradiation for anal cancer [44] also have high
rates of ED. Sexual problems are not exclusive to men who
have treatment to the pelvic organs. Hypogonadism and dam-
age to pelvic nerves may lead to sexual dysfunction after
intensive chemotherapy [26,45,46], or in men treated with
either pelvic radiotherapy or total body irradiation [39,47,48].
Survivors of testis cancer or lymphoma also may have excess
rates of sexual inactivity and low desire [49,50], though evi-
dence remains equivocal [51]. Causes may be multifactorial,
including hypogonadism, fatigue, and negative mood [45].
Animal studies suggest that obtaining erections several
times a week by using treatments such as phosphodiester-
ase-5-inhibitors, penile injection therapy, or vacuum erection
devices may protect the erectile tissue in the penis from atro-
phy, allowing better recovery of erections over time. Unfortu-
nately, adherence to such treatments, often called penile
rehabilitation, is so poor that it has been difficult to demon-
strate clear benefit [52].
2.2. Sexual problems in women
In women themost common sexual problems are vaginal dry-
ness and other genital changes that lead to pain during sexual
activity, or loss of sexual desire, usually accompanied by
difficulty feeling arousal and pleasure during sex [2]. Cancer
treatments that increase the risk of sexual dysfunction for
women include any that cause abrupt, premature ovarian
failure in women who had not yet begun menopause
[53,54]. Women whose combination chemotherapy leads to
permanent ovarian failure seem to have a higher risk for sex-
ual problems than those who continue to menstruate or have
just a temporary cessation of menses [55,56]. The risk of
permanent ovarian failure increases with the woman’s age,
especially for women over age 35, and with alkylating drugs
and higher total doses of chemotherapy. As inmen, any pelvic
radiation therapy contributes strongly to the risk of sexual
dysfunction, from a combination of ovarian failure and direct
tissue damage to genital areas in the radiation field
[11,19,39,57]. Use of gonadotropin agonists or antagonists to
create a temporary state of ovarian failure also causes sexual
problems, although the dysfunctions may resolve once hor-
monal therapy is discontinued [13]. Bilateral oophorectomy
increases the prevalence of sexual dysfunction whether per-
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women with genetic mutations that increase gynaecologic
cancer risk [54]. Although oestrogen replacement helps some-
what with vaginal dryness, it does not restore normal sexual
function [54]. Hormonal therapy also may cause sexual prob-
lems. Women given tamoxifen to prevent or treat breast can-
cer have negligible changes in sexual function if they did not
have prior chemotherapy [53,55], but aromatase inhibitors
may cause severe vaginal dryness and pain with sex [10,13].
At least a quarter of women who have systemic graft versus
host disease after allogeneic stem cell or bone marrow trans-
plantation develop irritation and then scarring on the vulva
and in the vagina. If not treated early, genital graft versus host
disease can make intercourse impossible, essentially obliter-
ating a woman’s vagina [58].
3. Communication about Sexual Function in
Oncology Practice
Although most research on communication about sexuality
between health care professionals (HCPs) and cancer patients
is qualitative, or based on surveys with limited numbers of
participants [59–61], results agree strongly on the major
issues, across developed countries. Cancer patients want
their HCPs to provide information and help with the sexual
consequences of cancer treatment, but rarely receive such
care [6,21,62]. HCPs believe that patients who want help with
sexuality will bring up the topic themselves [61,63]. Some
endorse the value of discussing sex with patients [63], but
each profession—oncologists, nurses, mental health profes-
sionals—fails to take responsibility to provide such discus-
sions, suggesting it is someone else’s job [43,64,65]. Barriers
to discussing sex cited by HCPs include lack of time, lack of
knowledge, a lack of a network of specialists who can act as
referrals, and personal discomfort with the topic of sexuality
[63,43,66–68]. HCPs tend to be most reluctant to discuss sex
with patients who are different from them, including oppo-
site gender, different sexual orientation, the unmarried, the
much younger or older, or patients from a different ethnicity
or culture [61,64]. Patients want help with a broad array of
sexual issues, not only including sexual function, but also
self-concept and relationships, whereas most HCPs discuss
sex at best in a narrow, medicalised fashion, focusing on
problems such as erectile dysfunction or vulvovaginal atro-
phy that would prevent penile/vaginal intercourse
[60,63,66,69–75]. HCPs report similar patterns of inadequate
communication about sexual issues in other areas of care,
such as cardiology [76], gynaecologic practice [77,78], general
practice [79,80], or psychological practice [81].
4. Assessment of sexual function
Although erections and vaginal blood flow can be measured
physiologically, most tests have limited relevance in clinical
practice for diagnosing sexual dysfunction or in creating a
treatment plan [82,83]. Since sexual desire, arousal, and
pleasure are subjective, assessment of changes with cancer
treatment often relies on interviews or patient-reported
outcome questionnaires [84]. A variety of standardisedquestionnaires have been used to assess sexual function
in oncology settings [84]. Some are specific to one type of
cancer, such as the Expanded Prostate Cancer Index Com-
posite (EPIC), which measures sexual function, urinary and
bowel incontinence, and symptoms related to hormonal
therapy [85]. The Female Sexual Function Index, a 19-item
multiple-choice measure for women, has been validated
for cancer patients [86]. In the United States, the National
Cancer Institute has sponsored research to create brief
screening questionnaires for cancer-related sexual dysfunc-
tion, as well as a larger bank of problem-specific items that
researchers can utilise for a particular research project
[69,87]. In Europe, the EORTC Quality of Life (QLG) Sexual
health working group has begun qualitative and survey
research to develop a more multifaceted Sexual Health
Measure for cancer patients and cancer survivors that will
include concepts such as body image, self-esteem, and rela-
tionship changes as well as assessing actual sexual function
(Elfriede Griemel, PhD, personal communication).
5. Interventions for cancer-related sexual
dysfunction
Fewer than 20% of most male or female cancer survivors seek
professional care (psychological or medical) for their sexual
problems [88–90], although close to half would like such help
if it were accessible and affordable [88,89]. Over half of men
who have radical prostatectomy get medical help for ED, but
their rates are exceptional because of surgeons’ attention to
preserving erectile function through penile rehabilitation
[62,91]. Sexuality is rated as a high priority issue by a quarter
to three-quarters of survivors [23,62,69], and is ranked as an
important unmet need during cancer survivorship
[23,42,62,92,93]. Sexual dysfunction after cancer is consis-
tently associated with poor perceived quality of life
[5,15,17,93–96].
6. Rationale for a multidisciplinary approach
Research on interventions to improve sexual function and
satisfaction in cancer patients and survivors suggests that
a multidisciplinary approach, combining medical and
psychosocial care, is the most effective strategy [2,97].
Although dysfunctions typically result from physiological
damage related to cancer treatment, resuming a satisfying
sex life requires good communication between partners
[98], taking a view that sexual pleasure and intimacy
may include a variety of activities besides penetrative
intercourse [73,97–100], and being able to cope with the
indignities and limitations of resuming sex after cancer.
Providing information and counselling early in the process
of treatment planning may be more effective than trying
to restore sexual function after problems have become
well-established [52,101].
Although a minority of men do try mechanical treatments
for ED, satisfaction and adherence remain poor [90,97]. In the
United States from 2003 to 2006, Medicare records of 39,000
men with localised prostate cancer showed that 26% used a
phosphodiesterase-5-inhibitor after radical prostatectomy,
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studies show that men on adjuvant hormonal therapy are
the least likely to use a medical treatment for erectile
dysfunction. A review of surveys on erectile dysfunction
treatment in prostate cancer survivors treated in academic
medical centres suggests that 38–52% use oral medication,
7–18% use penile injection therapy, 5–19% use a vacuum erec-
tion device, 4–10% try a urethral suppository, and only 2%
have penile prosthesis surgery [90,102–109]. Unfortunately,
utilisation of these treatments is well below 50% after several
months, except in men who have a penile prosthesis [110].
Barriers include the need to interrupt sexual activity, as well
as limited partner acceptance.
Similarly, in women it is rare that simple use of vaginal
dilation [111,112], lubricants [101], or oestrogen treatments
[53,54,101,113] restore the vulva and vagina to a problem-free
state. Vaginal dilation is best used as a preventive measure
rather than to treat established vaginal atrophy, but it is
difficult to convince women to use a dilator regularly [112].
However, innovative new vaginal moisturisers [114,115] and
selective oestrogen receptor modifiers [116,117] may provide
options to prevent and treat dyspareunia without increasing
cancer risk, especially when combined with sexual counsel-
ling [113,118].
7. Structure of a sexuality clinic in oncology
practice settings
One solution is better training for HCPs in general. A practical
model could focus on training one or several team members
(such as nurses, physician’s assistants, social workers, or psy-
chologists) in an oncology outpatient clinic to be the ‘repro-
ductive specialist’ who can assess patients’ concerns and
provide educational resources and brief sexual counselling,
using low intensity cognitive-behavioural therapy [119].
Patients who need more intensive medical treatment or cog-
nitive behavioural sex therapy could then be referred to
specialists.
Large cancer centres ideally should have in-house sexual
dysfunction clinics including specialists in mental health,
sexology, gynaecology, and urology, with outreach to cancer
site-specific clinics across the institution to educate and
encourage HCPs to ask about sexual issues, provide basic
information, and make referrals. Such clinics are far from
universally available, however. In community oncology offi-
ces or less specialised settings, such services are rarely
available. At best, oncologists, gynaecologists and urologists
provide purely medical suggestions and treatments. At least
in the United States, as well as some European countries,
poor insurance reimbursement for mental health care is a
barrier to establishing counselling and supportive services.
Furthermore, few mental health professionals who practice
in oncology settings have expertise in treatment of sexual
dysfunction. Conversely, most community-based specialists
in sexual problems have little knowledge of oncology. Each
practice setting should develop a referral network of in-
house or community urologists, andrologists, and gynaecol-ogists with expertise in treating medical aspects of sexual
dysfunction.
Once a triage system is set up, with trained reproductive
counsellors on the frontline and specialists available for
referrals, sexual rehabilitation can become a routine part
of quality care in oncology. Patients ideally should be
informed about potential problems at the time of treatment
planning. Further assessment of needs for help should take
place at each follow-up visit. One attractive approach is to
use electronic media to provide interactive, tailored educa-
tion and counselling for patients [120], supplementing with
human contact as needed [97,118]. When patients are trea-
ted at a tertiary referral centre away from home, telehealth
options such as realtime online support groups or providing
psychotherapy sessions via secure videochat may be help-
ful. Patients with chronically conflicted relationships [97]
or complicated sexual histories [121] may need referral to
a mental health professional with expertise in treating sex-
ual dysfunction.8. Priorities for research on sexuality and
cancer
For too long, researchers have focused on defining the preva-
lence and types of sexual problems after various cancer treat-
ments. Although some valuable work remains to be done on
comparative effectiveness of cancer treatments that differ
in their risk of reproductive side effects, the types of sexual
problems that commonly occur and the cancer treatments
that most increase risk for them are clear. The area that con-
tinues to be neglected is the design and evaluation of effective
interventions to prevent or treat cancer-related sexual dys-
function. In particular, mental health and medical specialists
need to collaborate to create cost-effective treatment
programs to help prevent, or at least better manage, sexual
problems that may interfere with adherence to life-saving
cancer treatments, and that clearly damage quality of life in
the long-term, even after successful cancer treatment. When
helping patients make shared decisions about treatment
options, a discussion of potential long-term sexual effects
should be included. After evaluating and refining interven-
tions, it will be important to study how best to disseminate
and implement them so that they reach not only the affluent,
educated patients treated at major urban cancer centres, but
also the larger majority of people who rarely have adequate
knowledge about cancer-related sexual problems, or skills
for coping with them.
As part of the EORTC Survivorship Summit, our working
group suggested the following high priority areas for research
and future clinical services:
• Create and evaluate cost-effective programs of education
and multidisciplinary treatment for sexual dysfunction
that can be applied across a variety of oncology treatment
settings
• Find ways to prevent cancer-related sexual dysfunction or
at least provide early intervention to minimise problems
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ment that will provide a comprehensive assessment of
sexual issues important to cancer survivors, including
physiological, psychological, and social aspects of
sexuality.9. The prevalence of cancer-related damage to
fertility
Cancer patients aged 44 or less at diagnosis make up about
13% of newly diagnosed cases worldwide [122]. Although
men 45 or older may still be interested in having future chil-
dren [123], this is the age group most at risk for distress when
childbearing is interrupted. Damage to fertility is usually
linked to particular cancer treatments, but some types of
cancer also may be associated with temporary or permanent
subfecundity. For example, men with testicular cancer often
have poor semen quality at diagnosis, and although most
have better values after treatment, those initial semen analy-
ses predict post-treatment sperm quality and genetic integ-
rity [124]. Indeed the risk of several types of cancer is
elevated in men with poor semen quality who present for
infertility treatment [125]. In women, too, childlessness is
associated with elevated risk of some types of ovarian cancer
[126] and with hormone-sensitive breast tumors [127].
Women with mutations in the BRCA1 gene also may have a
genetic risk for decreased ovarian reserve, leading to an ear-
lier average age at menopause [128].
In general however, it is the treatments used for cancer
that damage fertility. Chemotherapy regimens that include
alkylating drugs are associated with the highest risk of infer-
tility in both men and women, with damage to sperm or
oocytes increasing with drug dose [129]. The testes are even
more sensitive than the ovaries to damage from radiation
therapy [130]. The mechanisms of damage to fertility may
be similar for chemotherapy and for a significant dosage of
radiation to the gonads [129,130]. In the ovaries, one recent
theory is that the number of primordial follicles recruited
for growth accelerates, ultimately resulting in apoptosis of
successive waves of maturing oocytes, diminishing and ulti-
mately eradicating the supply [131]. Blood flow to the ovaries
has also been observed to decrease after some types of che-
motherapy, and certainly decreases with tissue damage from
radiation therapy [132]. Age is a greater factor in post-treat-
ment fertility for women than for men with cancer [133].
When women reach their mid- to late thirties, oocytes are
recruited and die at an accelerated rate, even without an envi-
ronmental risk factor [132].
Because fertility preservation is a new option, with high
costs and unknown long-term benefits, it would be helpful
to have criteria to optimise patient selection. Levels of
anti-mu¨llerian hormone (AMH), a marker of the number of
primordial follicles remaining in the ovaries, predict a
woman’s likelihood of having menstrual cycles after chemo-
therapy [133]. Very low levels of AMH are also associated with
poor response to ovarian stimulation [134]. Obtaining AMH
levels or using ultrasound imaging of the ovaries to examine
volume and antral follicle counts may give some idea of an
individual woman’s ovarian reserve before or after cancer
treatment, but neither measure is reliable enough to defini-tively guide decisions about whether a cycle of ovarian stim-
ulation would be worthwhile [134]. Recently, concerns have
been raised over the reliability of a new commercial AMH
assay used in most clinical settings [135]. International stan-
dards for AMH values are also still lacking [134].
A woman’s age, individual ovarian reserve, type and dose
of chemotherapy and/or dose of radiation to the ovaries give
a general idea of the likelihood that she will end up in perma-
nent, premature ovarian failure after cancer treatment, but
more prospective research is needed to develop predictive
algorithms to use in individual clinical-decisionmaking about
fertility preservation [132–135]. Many women under age 35 at
the time of cancer treatment will continue to menstruate or
will recover menstrual cycles, but because their ovarian
reserve has been depleted, they remain at significant risk to
reach menopause years earlier than normal [132]. Further-
more, the presence of menstrual cycles has been used as
the endpoint of much research on cancer and fertility, but is
far from a guarantee that conception will be possible [132].
With data from a number of registry-based studies,
becoming pregnant after completing cancer treatment does
not appear to increase the risk of disease recurrence, even
in women with hormone-positive breast cancer [136]. Occult
damage to heart or lung function after a woman’s cancer
treatment may occasionally cause unexpected health prob-
lems during a pregnancy. More often, women have birth com-
plications after cancer that include low birth weight infants,
premature birth, miscarriage, or neonatal death, particularly
in women who had uterine exposure to radiation in child-
hood [137].
For men, permanent infertility after cancer treatment
results when all stem cells in the testes have been destroyed
by either chemotherapy or radiation therapy [130,138]. About
3% to 18% of men are azoospermic at cancer diagnosis, before
receiving any treatment [139]. Even if no sperm are found in a
man’s semen, islands of sperm production may remain.
Exploration of the testes using microsurgery has allowed urol-
ogists to harvest mature sperm to use for cryopreservation
before cancer treatment or for fertility treatment after cancer
[139]. Recovery of spermatogenesis is common after chemo-
therapy or lower doses of radiation to the testes, but may take
several years [130,138].
10. Health of children born to cancer survivors
Large studies of children born to parents who were treated for
cancer before conception have largely been reassuring. No
excess rate of congenital abnormalities or genetic disease
has been found in offspring of childhood cancer survivors
[140,141], or in the offspring of young adults treated for cancer
[137]. Even most children exposed in utero to chemotherapy
during a mother’s cancer treatment for cancer appear to be
healthy, as long as treatment is delayed until the second tri-
mester of pregnancy [142].11. Techniques of fertility preservation
Sperm banking has been available for post-pubertal men fac-
ing cancer treatment for decades, but became more widely
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the early 1990s [130,138]. Even if only a few sperm cells with
poor motility survived freezing and thawing, they could be
used for conception with in vitro fertilisation. Still, records
of utilisation of cryopreserved semen in many large registries
continue to show that typically only about 10% to 20% of men
retrieve their samples for infertility treatment [143]. Most
men conceive using fresh sperm after cancer. Others die or
decide not to have children. Although a number of cancer
centres are cryopreserving small pieces of testicular tissue
obtained from prepubertal boys who undergo cancer treat-
ments with high risk of damaging fertility, we remain years
away from having a way to use these samples for conception
[130,138]. Human sperm cells have not yet been successfully
matured in vitro or by autografting the tissue onto an immu-
nodeficient mouse host. Autotransplantation of testicular
tissue risks reintroducing cancer cells. A hope is that sper-
matogonial stem cells that manufacture sperm cells can be
isolated and used to repopulate the cancer survivor’s testis,
but attempts have not been successful in humans [130].
Fertility preservation is evenmore complicated and expen-
sive in women. For prepubertal girls, the only current option is
again the experimental one of retrieving ovarian tissue for
cryopreservation [144]. Later optionswould include autotrans-
plantation of the thawed tissue, with its attendant risks of a
cancer recurrence, or using primordial follicles with in vitro
maturation, another procedure that is not yet technically pos-
sible, though advances are being made [145]. Recently, a live
birth was reported after conception using a metaphase II
oocyte harvested from the ovary of a young woman with ovar-
iancancerandmatured in vitrobeforebeing fertilised in the lab-
oratory [146]. Ovarian tissue cryopreservation is still
consideredexperimental by theAmericanSocietyofReproduc-
tive Medicine [147], and autotransplantation of ovarian tissue
has resulted in fewer than 30 live births worldwide [148]. It is
nowpossible,however, tobeginovarianstimulation for fertility
preservation at any point in themenstrual cyclewith excellent
results, so that the cycle can usually be accomplished in less
than 2 weeks [149], minimising delays in starting cancer treat-
ment. Since birth rates are now equal using cryopreserved
oocytes subsequently thawedand fertilised, compared to those
fromusing cryopreserved embryos, the options have increased
for young cancer patients who are not in a stable relationship
[148]. For women with breast cancer, protocols using letrozole
as part of ovarian stimulation canminimise peak estradiol lev-
els during fertility preservationwithout compromising results,
potentiallydecreasing the risk thata cycleofhormonestimula-
tion would lead to cancer recurrence [149].
Cancer treatments can sometimes bemodified to spare fer-
tility, for example avoiding the use of alkylating chemotherapy
in treating Hodgkin lymphoma when the cancer prognosis is
favourable [150,151]. When women are going to have pelvic
radiotherapy, ovarian transposition (moving the ovaries out
of the field tominimise their exposure) can often preserve hor-
monal function and fertility, though uterine capacity may still
be damaged [152]. Other options that may be successful for
both cancer treatment and fertility preservation include coni-
sation for noninvasive cervical malignancies, trachelectomy
for very early stage cervical cancer, which spare the uterus
and ovaries [153], conservative surgery for germ cell, border-line, or early stage epithelial ovarian tumors [154], and treat-
ment of early stage uterine cancer with progestogen therapy,
followed by hysterectomy after pregnancy [155].
12. Utilisation of fertility preservation
Sperm banking, a relatively inexpensive and medically
uncomplicated procedure, remains underutilised in indus-
trialised nations [138,156], even in countries whose universal
health system pays for sperm banking [157]. In a recent Swed-
ish registry-based cohort, however, 68% of men recalled
getting information on sperm banking and 54% preserved
semen [158]. The most common barrier remains failure to
get information to male patients in a timely way in oncology
treatment settings [159]. The oncologist’s recommendation is
a crucial factor [155,156,159]. For teens, it is important to
include the parents in the education and counselling as part
of the decision process [160]. Despite relatively low rates of
utilisation of banked semen, sperm banking remains a simple
and effective type of fertility preservation. In a recent study of
men treated for Hodgkin lymphoma, semen cryopreservation
doubled the odds of fatherhood after treatment, with 20% of
children conceived using cryopreserved semen [161].
Even fewer eligible women undergo some type of fertility
preservation. The out-of-pocket costs to undergo ovarian
stimulation or surgery to retrieve ovarian tissue for storage
vary widely across the world. A high cost for in vitro fertilisa-
tion not only decreases the rate of usage in a nation’s women,
but also influences the number of embryos placed in a trans-
fer cycle, with higher costs of care leading to the adverse out-
come of more multiple births [162]. In the United States,
where insurance rarely covers ovarian stimulation, only 12%
of infertile women use any infertility services, with the great
majority only having a medical consultation [163]. Women
who use assisted reproductive technology are older, more
affluent and educated, and more likely to be Caucasian
[163]. These same demographic trends are seen in the small
percentage of United States women with cancer who undergo
fertility preservation [164–166]. Yet even in Canada, where fer-
tility preservation is included in national health insurance,
fewer than 5% of eligible women appear to have fertility pres-
ervation before cancer treatment [167]. In one academic cen-
tre in the Netherlands, only 2% of women had fertility
preservation [168]. Young girls or adult women are less likely
than men to be informed about fertility preservation [169]. In
the same Swedish cohort with such high rates of sperm bank-
ing, only 12% of women had been offered fertility preserva-
tion and 2% proceeded [158]. Some women could only have
a biological child with the help of a gestational carrier, but
restrictive laws in many European states forbid such arrange-
ments, leaving opportunities only for those wealthy enough
to afford reproductive ‘tourism,’ with the added concern of
exploitation of women living in poverty [170].13. Information, decisional support, and
counselling about fertility preservation
Surveys of adolescents and young adults with cancer show
that a majority want information on damage to fertility and
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 4 1 –5 3 47options for parenthood, particularly those who have not yet
begun having children [151,171–176]. Despite guidelines on
counselling patients about fertility preservation originally
published in 2006 by the American Society of Clinical
Oncology, two surveys conducted several years later found
than fewer than half of oncologists in the United States were
making routine referrals [177,178]. In a recent survey of 100
oncologists in the United Kingdom, only 38% routinely pro-
vided written material on fertility preservation to eligible
patients [179]. Despite a national system of sperm banking
for oncology patients in the United Kingdom, 21% of cancer
specialists who responded to a survey were unfamiliar with
local policies, and many let their own beliefs influence which
men they referred [180]. In a study of French oncologists, 54%
had not referred a single female patient for fertility preserva-
tion in the past 6 months [181]. Common barriers found in
research on oncologist communication include lack of time
in busy clinics, lack of knowledge about fertility preservation,
and not knowing how or where to refer patients. In addition,
many oncologists do not discuss fertility preservation if they
believe a patient would not be able to afford it financially, or if
a patient has a poor prognosis or already has at least one
child.
Some evidence already suggests that having the opportu-
nity to consider fertility preservation and to make an
informed decision can improve well-being in cancer survivors
[182]. Actually storing reproductive material helps patients
feel more optimistic about the future [182,183]. A survey of
young women treated for cancer, 10 years after their diagno-
sis, revealed that those who had wanted a child and were
unable subsequently to fulfil their desire remained signifi-
cantly distressed about infertility [184]. Childless women
were affected the most severely. A recent survey of young
cancer survivors in Germany also found unmet needs for
information and lingering distress, especially in women [185].
Because decisions about preserving fertility are complex
and usually must be made within a narrow window of time
that is already extremely stressful because of the unexpected
diagnosis of cancer, efforts are being made to create educa-
tional materials and decision aids for patients [186–189].
Although the science of decision-making in health settings
is advancing, few studies have evaluated the long-term out-
comes of decision-aids on cancer patients’ well-being [190].
More work is needed to find the best ways to educate patients
about cancer-related infertility and to help them make
choices that will improve their future satisfaction with life.14. Parenthood options after successful cancer
treatment
The major focus of research on fertility and cancer has
been on modalities to prevent damage from cancer treat-
ment. However, as illustrated above, the majority of cancer
survivors who want to have children do not have cryopre-
served genetic material. Women may want evaluation of
their current ovarian reserve to help in deciding whether
to try to conceive naturally, pursue assisted reproductive
technology, or consider social parenthood by means of
donated oocytes or embryos, or adoption [132,184]. Menoften have not had a recent semen analysis, and are unsure
whether they could father a pregnancy [143]. Although can-
cer survivors express more comfort with adoption than
with using donor sperm or oocytes [171,172], their medical
history may be a barrier to adopting in many international
or domestic contexts [191]. One solution would be a multi-
disciplinary clinic that could assess current fertility in can-
cer survivors, offer appropriate options for fertility
treatment, and also provide education and counselling on
options to become a parent or to resolve grief about can-
cer-related infertility.
15. Priorities for research and clinical services
regarding cancer and fertility
The working group suggests the following priorities related to
cancer and fertility:
• Establish a European registry, including biomarkers that
could be used to predict infertility in response to specific
cancer treatments. Include periodic standardised surveys
about clinical services such as counselling and referral
regarding fertility preservation
• Create tools to facilitate shared decision-making for
patients who are at risk for infertility from cancer
treatment
• Create multidisciplinary programs to assess fertility after
cancer treatment, help patients to make decisions about
parenthood, and to offer a range of options for patients
to become parents.
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